A5040731381- Cancer Immunotherapy and Biomarkers
- Orthodontics and Dentofacial Orthopedics
- dental development and anomalies
- CAR-T cell therapy research
- Dental Implant Techniques and Outcomes
- Cancer Genomics and Diagnostics
- Dental Radiography and Imaging
- Immunotherapy and Immune Responses
- Organ Transplantation Techniques and Outcomes
- Fungal Biology and Applications
- Colorectal Cancer Treatments and Studies
- BRCA gene mutations in cancer
- Microbial Natural Products and Biosynthesis
- Gastric Cancer Management and Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Temporomandibular Joint Disorders
- Medicinal Plants and Bioactive Compounds
- Sepsis Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Chronic Myeloid Leukemia Treatments
- PARP inhibition in cancer therapy
- Forensic Anthropology and Bioarchaeology Studies
- Genomics and Phylogenetic Studies
- Periodontal Regeneration and Treatments
Sichuan University
2020-2025
State Key Laboratory of Oral Diseases
2023-2025
Stomatology Hospital
2024-2025
Jiujiang First People's Hospital
2024
Hangzhou Quality and Technical Supervision and Testing Institute
2024
Regeneron (United States)
2023
Anhui University of Traditional Chinese Medicine
2021
Zhejiang University
2014-2020
Children's Hospital of Zhejiang University
2020
Sun Yat-sen University
2010
Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required extend this benefit beyond subset patients. In preclinical models tumour-derived VEGF limits cell activity while anti-VEGF augments intra-tumoral T-cell infiltration, potentially through vascular normalization and endothelial activation. This study investigates how blockade with bevacizumab could potentiate PD-L1 inhibition atezolizumab mRCC....
1009 Background: Atezolizumab (atezo; MPDL3280A) is a humanized MAb that inhibits binding of PD-L1 to PD-1 and B7.1, thus restoring tumor-specific T-cell immunity. Atezo has single-agent activity in mTNBC. Combining atezo with chemotherapy hypothesized enhance immunity by exposing the immune system high levels tumor antigens modulating NK cell functions. This arm Phase Ib study evaluated + nab-paclitaxel (pac) patients (pts) mTNBC treated ≤ 3 prior lines therapy. Methods: Primary endpoints...
Abstract Objective The main objective was to analyse the clinical effectiveness of ramus mini-implant-assisted traction mandibular second molars with eruption disturbances. Materials and Methods A prospective study carried out during a 3-year period. total 16 patients 19 impacted underwent surgical exposure followed by implant-assisted orthodontic traction. pre- post-treatment cone-beam computed tomography, pre-, in-, panoramic radiographs were collected measured for changes in space, angles...
673 Background: Blockade of the PD-L1/PD-1 axis is a proven immunologic approach for treatment many cancers; however, not all pts respond to monotherapy. Bev, an anti–VEGF-A antibody, has demonstrated clinical efficacy in mCRC and enhanced T-cell infiltration tumors preclinical studies. Thus, we postulated that combining atezo (anti-PD-L1) with bev would augment anti-tumor immune responses, resulting improved more durable benefit. We report results from first study anti-PD-L1 agent + VEGF-A...
12000 Background: PD-L1 expression has limitations as a biomarker for checkpoint immunotherapy (CI). Prior atezolizumab (atezo) monotherapy studies suggest improved efficacy in high tissue tumor mutational burden (tTMB-H) cohorts. We report large retrospective analysis associating tTMB with neoantigen load (NAL) and CI across multiple studies, types lines of therapy. Methods: Tissue TMB was evaluated by the FoundationOne (F1) assay 7 atezo studies: NSCLC n= 342 (FIR, BIRCH, POPLAR, OAK),...
Abstract Genetic and epigenetic alterations can distinguish cancer cells from their normal counterparts, allowing tumors to be recognized as foreign by the immune system. The system's ability detect destroy these abnormal is foundation of immunotherapy. In order for this occur must traffic persist in tumors. Programmed death-ligand 1 (PD-L1; also called B7-H1 or CD274), which expressed on many tumor-infiltrating cells, plays an important part blocking immune-mediated tumor cell destruction...
To develop an artificial intelligence (AI) system for automatic palate segmentation through CBCT, and to determine the personalized available sites palatal mini implants by measuring bone soft tissue thickness according AI-predicted results.Eight thousand four hundred target slices (from 70 CBCT scans) from orthodontic patients were collected, labelled well-trained orthodontists randomly divided into two groups: a training set test set. After deep learning process, we evaluated performance...
This study aimed to evaluate the biomechanical effects of aligner overtreatment on molar distalization using clear aligners.
ABSTRACT Currently, medical device eye irritation testing relies on the Draize test in rabbits, which presents significant challenges regarding animal welfare and variations across laboratories. This research explores application of commercially available three‐dimensional reconstructed human corneal epithelial tissue (Skinovo‐Ocular) evaluation. The model is developed by culturing immortalized cells at a liquid‐air interface, resembling morphology induction biological indicators found...
Cordycepol C, a novel sesquiterpene isolated from the cultured mycelia of Cordyceps ophioglossoides, contains hydroperoxy group and is cytotoxic to HepG2 cells. So far, no sesquiterpenes have been found in genus it would be interesting investigate antitumor efficacy as well mechanism action this unusual sesquiterpene. In study, we showed that cordycepol C induced apoptosis cells without affecting normal liver cell line L-02. caused poly(ADP-ribose)polymerase-1 (PARP-1) cleavage triggered...
The effects of ischemic postconditioning (IPostC) on ischemia reperfusion (IR) injury liver grafts was examined in rats after orthotopic transplantation (OLT).Male Wistar were used as donors and recipients to establish a model. animals randomly divided into four groups: sham-operated (SO, n = 6), IR (n IPostC1 6) IPostC2 6). IPostC achieved by several intermittent interruptions blood flow the early phase reperfusion. Several parameters hepatic damage, oxidative stress, neutrophil...
Purpose This research was designed to elucidate the anti-inflammatory impacts of liquiritin on lipopolysaccharide (LPS)-activated human corneal epithelial cells (HCECs).
A cryptic gene cluster, bln, was activated by genome mining in Tolypocladium ophioglossoides. This activation led to the production of balanol and eight other metabolites. Gene disruption metabolite profile analysis showed that biosynthesis involved convergence independent PKS NRPS pathways, a biosynthetic pathway for proposed.
Abstract We retrospectively investigated the pharmacokinetics and exposure‐efficacy/safety relationships of single‐agent atezolizumab based on tissue tumor mutational burden (tTMB) status (high vs low [≥16 <16 mutations/megabase]) in a pan‐tumor population from seven clinical trials. Data sources included OAK, POPLAR, BIRCH, FIR, IMvigor210, IMvigor211, PCD4989g studies; 986 2894 treated patients (34%) had TMB data. Exposure metrics were obtained using prior two‐compartment...
<title>Abstract</title> <bold>Introduction</bold>: The objective of this study was to analyze the biomechanical effects aligner overtreatment on molar distalization with clear aligners. <bold>Methods</bold>: Various models comprising maxillary dentition, maxilla, periodontal ligaments, attachments, and aligners were meticulously crafted integrated into finite-element software. Six distinct devised for analysis. first three examined second aligner, different configurations i.e., no...
TPS530 Background: CIT has demonstrated significant survival benefits across multiple cancers. Despite remarkable success, only subsets of pts derive clinical benefit from monotherapy. Thus, combinations may be needed to address the mechanisms that allow cancers escape antitumor immunity. However, a large number potential would have tested identify an effective combination regimen. The MORPHEUS platform consists multiple, global, open-label, randomized Phase Ib/II trials designed assess...
TPS4134 Background: Multiple cancers have been treated successfully with CIT; nonetheless, only subsets of pts experience durable response CIT monotherapy. combinations may therefore be needed to simultaneously address multiple mechanisms cancer immune evasion. The MORPHEUS platform consists multiple, global, open-label, randomized Phase Ib/II trials designed investigate in different tumor types. Using a trial design, combination arms will compared single control arm. Furthermore, the design...
This study aims to determine the reproducibility and location-stability of cone-beam computed tomography (CBCT) radiomic features.
Abstract Background: Metastatic pancreatic ductal adenocarcinomas (mPDACs) express high levels of the adenosine-generating enzyme CD73 and therapeutically represent a significant unmet medical need, with median patient overall survival (OS) &lt;1 year. The small-molecule quemliclustat (quemli; AB680) was designed to inhibit soluble cell-bound enzymatic activity, thereby providing capability reversing adenosine-mediated anti-tumor immune suppression. Quemli, in combination...